High-intensity Focused Ultrasound Therapy Market Size, Share, Growth, and Industry Analysis, By Type (Non-invasive Treatment, Minimal Invasive Treatment), By Application (Liver tumor, Breast cancer and breast fibroadenoma, Prostate cancer and benign prostate diseases, Hysteromyoma, Other), Regional Insights and Forecast to 2035

High-intensity Focused Ultrasound Therapy Market Overview

The global High-intensity Focused Ultrasound Therapy Market size estimated at USD 311.25 million in 2026 and is projected to reach USD 1215.09 million by 2035, growing at a CAGR of 16.34% from 2026 to 2035.

The high-intensity focused ultrasound therapy market is expanding rapidly due to increasing adoption of non-invasive cancer treatment technologies across hospitals and specialty clinics. High-intensity focused ultrasound therapy systems are used in more than 1,850 medical facilities globally for tumor ablation and therapeutic tissue destruction. Non-invasive treatment procedures accounted for 67% of total HIFU therapy procedures during 2025 because recovery times are reduced by nearly 45% compared with surgical interventions. Prostate cancer applications represented 31% of global HIFU procedure volume. Asia-Pacific contributed 42% of worldwide HIFU therapy installations due to rising oncology treatment infrastructure. MRI-guided HIFU systems accounted for 38% of newly installed therapeutic ultrasound platforms in 2025.

The United States high-intensity focused ultrasound therapy market represented 29% of global clinical procedure volume during 2025 due to advanced oncology infrastructure and rising prostate disease prevalence. More than 320 hospitals and cancer treatment centers in the U.S. used high-intensity focused ultrasound therapy systems for non-invasive procedures during 2024. Prostate cancer treatment accounted for 44% of HIFU procedures performed nationwide. MRI-guided HIFU platforms represented 53% of newly approved therapeutic ultrasound installations in the country. California, Texas, and New York collectively contributed 36% of U.S. HIFU treatment procedures. Non-invasive uterine fibroid therapy procedures increased by 22% between 2023 and 2025 due to shorter hospitalization periods and reduced post-treatment complications.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Rising preference for non-invasive oncology procedures contributed 64% of high-intensity focused ultrasound therapy demand, while reduced hospitalization requirements influenced 58% of patient treatment decisions globally.
• Major Market Restraint: High treatment equipment costs affected 49% of healthcare facilities, while limited reimbursement coverage influenced 41% of delayed HIFU therapy adoption across developing healthcare systems.
• Emerging Trends: MRI-guided therapy systems increased by 37%, while robotic-assisted high-intensity focused ultrasound therapy procedures expanded by 29% during 2025 across oncology treatment centers.
• Regional Leadership: Asia-Pacific accounted for 42% of global HIFU therapy installations, while North America represented 31% of advanced MRI-guided therapeutic ultrasound procedures worldwide.
• Competitive Landscape: Top five manufacturers controlled 61% of global high-intensity focused ultrasound therapy equipment production, while oncology-focused product portfolios represented 57% of competitive innovations.
• Market Segmentation: Non-invasive treatment systems held 67% market share, while prostate cancer and benign prostate disease applications accounted for 31% of global HIFU procedures.
• Recent Development: AI-assisted treatment planning systems increased by 26%, while real-time thermal monitoring integration expanded by 33% among HIFU therapy manufacturers during 2024 and 2025.

High-intensity Focused Ultrasound Therapy Market Latest Trends

The high-intensity focused ultrasound therapy market is witnessing rapid technological advancement due to increasing demand for non-invasive therapeutic procedures in oncology and gynecology applications. MRI-guided HIFU systems accounted for 38% of new therapeutic ultrasound installations during 2025 because clinicians require higher targeting precision for tumor ablation. Robotic-assisted HIFU procedures increased by 24% between 2023 and 2025 across advanced cancer treatment centers. Prostate cancer treatment represented 31% of total global HIFU procedures due to rising prevalence among men above 55 years of age.

AI-assisted treatment planning software improved targeting accuracy by 18% in liver tumor and breast fibroadenoma procedures. Real-time thermal imaging integration expanded by 33% because continuous temperature monitoring reduced tissue damage risks by 16%. Non-invasive HIFU therapy systems reduced patient recovery periods by 41% compared with surgical interventions. Portable therapeutic ultrasound platforms increased by 19% in outpatient care facilities during 2025. Asia-Pacific accounted for 42% of new HIFU therapy installations because China, Japan, and South Korea expanded oncology infrastructure significantly. Hospital adoption of ultrasound-guided HIFU systems increased by 27% across Europe during 2024. Multi-frequency transducer technology improved treatment efficiency by 21% in uterine fibroid procedures.

High-intensity Focused Ultrasound Therapy Market Dynamics

DRIVER

"Increasing demand for non-invasive cancer treatment procedures."

The growing preference for non-invasive therapeutic technologies has significantly accelerated high-intensity focused ultrasound therapy adoption worldwide. More than 58% of oncology specialists preferred HIFU therapy for localized tumor treatment because post-operative complications remain substantially lower than conventional surgeries. Non-invasive treatment systems reduced hospitalization periods by 43% in prostate cancer procedures during 2025. Prostate disease treatment accounted for 31% of HIFU procedure volume globally due to rising prevalence among aging populations. MRI-guided HIFU therapy systems improved tumor targeting precision by 22%, encouraging wider adoption in advanced oncology centers. Hospitals implementing HIFU platforms reported 17% lower patient recovery times compared with traditional surgical approaches. Asia-Pacific oncology infrastructure expansion increased therapeutic ultrasound procedure volumes by 26% between 2023 and 2025.

RESTRAINT

"High installation and treatment equipment costs."

High-intensity focused ultrasound therapy systems require advanced imaging and thermal monitoring technologies, increasing installation costs for healthcare facilities. MRI-guided HIFU systems represented 38% of equipment installations but required 29% higher infrastructure investment than ultrasound-guided systems. Approximately 47% of mid-sized hospitals delayed HIFU equipment procurement during 2024 because of capital expenditure limitations. Maintenance expenditures for therapeutic ultrasound transducers increased by 14% due to precision calibration requirements. Limited reimbursement support affected 41% of patient adoption in developing healthcare systems. Healthcare facilities in emerging economies experienced 18% lower utilization rates because trained HIFU specialists remained insufficient. Multi-frequency therapeutic systems increased operational costs by 16% in oncology centers. Infrastructure limitations restricted 21% of smaller hospitals from implementing MRI-compatible HIFU platforms.

OPPORTUNITY

"Expansion of therapeutic ultrasound applications beyond oncology."

High-intensity focused ultrasound therapy applications expanded rapidly into neurology, cardiology, and cosmetic treatment segments during 2025. Neurological disorder treatment procedures increased by 19% due to successful implementation in essential tremor and Parkinson’s disease management. Cardiology-focused HIFU applications represented 11% of newly approved clinical trial programs globally. Uterine fibroid treatment procedures expanded by 23% across women’s health clinics because non-invasive therapy reduced recovery periods by 38%. Portable HIFU systems designed for outpatient centers increased by 17% during 2025. Asia-Pacific healthcare facilities expanded gynecological HIFU treatment capacity by 24% between 2023 and 2025. AI-assisted targeting software improved treatment planning efficiency by 21%, creating stronger opportunities for automated therapeutic ultrasound systems. Minimally invasive combination therapies integrating HIFU with immunotherapy increased by 13% across advanced oncology research facilities.

CHALLENGE

"Technical limitations and requirement for specialized expertise."

High-intensity focused ultrasound therapy procedures require precise imaging guidance and skilled operators to ensure effective treatment outcomes. Approximately 34% of healthcare providers reported challenges related to operator training and real-time monitoring accuracy during 2024. MRI-guided systems required 27% longer procedure preparation times compared with standard ultrasound-guided treatments. Tissue movement during respiratory cycles affected 16% of liver tumor treatment procedures, reducing targeting precision. Limited availability of trained HIFU specialists impacted 23% of treatment centers globally. Thermal dose monitoring errors contributed to 9% of procedural complications in advanced oncology applications. Small healthcare facilities experienced 18% longer equipment maintenance downtime due to lack of technical expertise. Regulatory approval procedures for advanced therapeutic ultrasound systems increased product launch timelines by 14% during 2025.

High-intensity Focused Ultrasound Therapy Market Segmentation

Download Free Sample to learn more about this report.

The high-intensity focused ultrasound therapy market is segmented by type and application based on treatment methodology and clinical usage. Non-invasive treatment systems accounted for 67% of global installations during 2025 because they reduce hospitalization and post-treatment complications significantly. Minimal invasive treatment platforms represented 33% of demand linked to advanced targeted oncology procedures. By application, prostate cancer and benign prostate diseases held 31% market share due to increasing elderly male population and rising prostate disorder prevalence. Liver tumor applications contributed 22% of therapeutic procedure volume. Hysteromyoma treatment accounted for 18% of installations due to expanding women’s healthcare adoption. Breast cancer and fibroadenoma procedures represented 15% of total HIFU treatment demand globally.

BY TYPE

Non-invasive Treatment: Non-invasive treatment systems dominated the high-intensity focused ultrasound therapy market with 67% share during 2025 because they eliminate surgical incisions and reduce recovery periods significantly. Hospitals represented 61% of non-invasive HIFU installations due to growing oncology treatment demand. MRI-guided systems accounted for 41% of non-invasive therapy platforms because real-time imaging improves tumor targeting precision. Prostate cancer procedures contributed 33% of non-invasive treatment volume globally. Asia-Pacific represented 44% of non-invasive HIFU system installations due to rapid expansion in cancer treatment infrastructure. Patient hospitalization periods decreased by 43% with non-invasive HIFU therapy compared with conventional surgeries. Real-time thermal monitoring technologies improved treatment accuracy by 19% in liver tumor procedures. Portable ultrasound-guided HIFU systems increased by 17% across outpatient treatment centers during 2025.

Minimal Invasive Treatment: Minimal invasive treatment systems accounted for 33% of global high-intensity focused ultrasound therapy demand during 2025 due to rising adoption in targeted oncology procedures. Breast cancer and fibroadenoma treatments represented 24% of minimal invasive HIFU applications because localized tissue ablation requires higher precision. MRI-compatible minimally invasive systems improved targeting accuracy by 21% during gynecological procedures. North America contributed 36% of minimal invasive treatment installations due to advanced imaging infrastructure. Therapeutic ultrasound procedures combined with minimally invasive catheter technologies increased by 16% between 2023 and 2025. Hospitals implementing minimally invasive HIFU therapy reduced patient recovery time by 31% compared with surgical alternatives. Multi-frequency transducer systems represented 29% of minimal invasive installations due to higher tissue penetration efficiency. Robotic-assisted minimally invasive HIFU procedures expanded by 18% globally during 2025.

BY APPLICATION

Liver tumor: Liver tumor applications accounted for 22% of global high-intensity focused ultrasound therapy procedures during 2025 because liver cancer incidence remained high across Asia-Pacific countries. China represented 39% of liver tumor HIFU procedures due to increasing hepatocellular carcinoma prevalence. MRI-guided therapeutic systems improved liver tumor targeting precision by 18% during clinical procedures. Non-invasive HIFU treatment reduced hospitalization periods by 36% compared with conventional liver surgeries. Hospitals accounted for 72% of liver tumor HIFU installations because advanced oncology infrastructure is required for precision imaging. Ultrasound-guided systems represented 57% of liver tumor procedures due to lower operational costs. Real-time thermal monitoring reduced surrounding tissue damage risks by 14% during liver ablation procedures.

Breast cancer and breast fibroadenoma: Breast cancer and breast fibroadenoma applications represented 15% of high-intensity focused ultrasound therapy procedures globally during 2025. Non-invasive breast fibroadenoma treatment procedures increased by 21% because cosmetic outcomes improved significantly compared with surgical excision. Europe accounted for 29% of breast-related HIFU applications due to expanding women’s healthcare programs. MRI-guided systems represented 46% of breast tumor treatment procedures because imaging precision remains critical for tissue preservation. Outpatient treatment centers contributed 18% of breast fibroadenoma HIFU procedures during 2025. Recovery periods declined by 39% among patients treated with therapeutic ultrasound systems. AI-assisted imaging software improved lesion localization accuracy by 17% during breast-focused HIFU therapy procedures.

Prostate cancer and benign prostate diseases: Prostate cancer and benign prostate diseases dominated the high-intensity focused ultrasound therapy market with 31% share during 2025. Men above 55 years accounted for 68% of HIFU prostate procedures globally. North America represented 34% of prostate-focused therapeutic ultrasound treatments due to rising prostate disease prevalence. Non-invasive treatment systems accounted for 73% of prostate procedures because patient recovery periods were reduced by 42%. MRI-guided HIFU systems improved prostate lesion targeting accuracy by 23% during focal therapy applications. Hospitals using robotic-assisted HIFU platforms increased by 19% between 2023 and 2025. Ultrasound-guided systems represented 52% of prostate treatment procedures due to lower equipment costs. Patient readmission rates declined by 16% following HIFU prostate therapy compared with conventional surgeries.

Hysteromyoma: Hysteromyoma applications accounted for 18% of global high-intensity focused ultrasound therapy procedures during 2025 because non-invasive uterine fibroid treatment adoption expanded rapidly. Asia-Pacific represented 47% of hysteromyoma HIFU procedures due to increasing women’s healthcare infrastructure. MRI-guided therapeutic ultrasound systems accounted for 38% of fibroid treatment installations because precise thermal ablation is essential. HIFU treatment reduced hospitalization periods by 41% compared with hysterectomy procedures. Women aged between 35 and 50 represented 63% of hysteromyoma treatment procedures globally. Outpatient gynecology centers increased HIFU treatment adoption by 22% during 2024. Real-time temperature monitoring technologies reduced tissue damage risks by 13% during uterine fibroid therapy procedures.

Other: Other applications accounted for 14% of high-intensity focused ultrasound therapy demand, including neurological disorders, pancreatic tumors, and cosmetic medicine. Neurological treatment procedures increased by 19% during 2025 because HIFU systems gained wider acceptance in essential tremor management. Cardiology-focused therapeutic ultrasound procedures represented 8% of other application demand globally. Europe contributed 26% of non-oncology HIFU treatment procedures due to strong clinical research activity. AI-assisted treatment planning systems improved targeting precision by 18% in neurological applications. Cosmetic medicine clinics accounted for 12% of other HIFU therapy procedures linked to non-surgical skin tightening treatments. Portable therapeutic ultrasound systems expanded by 15% across outpatient specialty centers during 2025.

High-intensity Focused Ultrasound Therapy Market Regional Outlook

Download Free Sample to learn more about this report.

The high-intensity focused ultrasound therapy market demonstrated strong regional growth during 2025 due to expanding oncology infrastructure and increasing demand for non-invasive procedures. Asia-Pacific accounted for 42% of global HIFU installations because China, Japan, and South Korea invested heavily in therapeutic ultrasound technologies. North America represented 31% of advanced MRI-guided HIFU procedures globally. Europe contributed 21% of worldwide treatment volumes linked to rising adoption in gynecology and oncology applications. Middle East & Africa held 6% market share supported by growing cancer treatment infrastructure. Non-invasive treatment systems represented more than 65% of installations across all major regions during 2025.

NORTH AMERICA

North America accounted for 31% of global high-intensity focused ultrasound therapy demand during 2025 because of advanced healthcare infrastructure and increasing prostate cancer treatment adoption. The United States represented 82% of regional HIFU procedure volume due to strong oncology treatment capabilities. More than 420 hospitals and specialty treatment centers across North America implemented therapeutic ultrasound systems during 2024. Prostate cancer applications accounted for 37% of regional HIFU procedures because prostate disease prevalence increased significantly among men above 55 years. MRI-guided HIFU systems represented 54% of newly installed platforms due to superior imaging precision. Canada contributed 11% of regional installations linked to expanding gynecology treatment infrastructure. Robotic-assisted therapeutic ultrasound procedures increased by 18% between 2023 and 2025 across advanced oncology centers. Non-invasive treatment systems reduced patient recovery periods by 43% compared with surgical procedures. Hospitals implementing AI-assisted thermal monitoring technologies improved treatment precision by 16%. Outpatient HIFU treatment centers expanded by 14% during 2025 due to increasing patient preference for same-day procedures.

EUROPE

Europe represented 21% of global high-intensity focused ultrasound therapy installations during 2025 due to rising adoption in oncology and women’s health applications. Germany, France, and the United Kingdom collectively accounted for 57% of European therapeutic ultrasound procedures. Hysteromyoma treatment represented 24% of regional HIFU applications because non-invasive fibroid therapy gained wider clinical acceptance. MRI-guided systems accounted for 48% of European installations linked to advanced imaging infrastructure. Non-invasive treatment platforms reduced post-operative complications by 19% across oncology procedures. Hospitals represented 68% of regional therapeutic ultrasound installations during 2025. Robotic-assisted HIFU systems expanded by 17% across European cancer treatment centers. AI-assisted imaging software improved lesion localization accuracy by 18% in breast cancer procedures. Outpatient treatment centers increased by 13% due to rising demand for minimally disruptive therapies. Italy and Spain collectively represented 22% of regional gynecological HIFU procedures because women’s healthcare modernization programs expanded rapidly. Portable therapeutic ultrasound systems increased by 15% across specialty clinics during 2024.

ASIA-PACIFIC

Asia-Pacific dominated the global high-intensity focused ultrasound therapy market with 42% share during 2025 due to rapid healthcare infrastructure expansion and rising cancer incidence. China represented 46% of regional HIFU installations because therapeutic ultrasound systems are widely used in liver tumor and uterine fibroid treatment. Japan contributed 18% of Asia-Pacific procedure volume linked to advanced imaging technology adoption. Non-invasive treatment systems accounted for 71% of regional HIFU procedures because hospitals prioritized shorter recovery periods. Liver tumor applications represented 27% of Asia-Pacific therapeutic ultrasound procedures during 2025. MRI-guided systems increased by 24% between 2023 and 2025 due to precision treatment requirements. India contributed 14% of regional installations because oncology infrastructure expanded rapidly across metropolitan hospitals. Outpatient gynecology centers increased HIFU therapy adoption by 21% during 2024. Multi-frequency transducer technology improved tissue penetration efficiency by 19% in Asian oncology facilities. Government-supported cancer treatment modernization programs increased therapeutic ultrasound equipment procurement by 23% across regional hospitals.

MIDDLE EAST & AFRICA

Middle East & Africa accounted for 6% of global high-intensity focused ultrasound therapy demand during 2025 due to gradual expansion of oncology infrastructure and rising awareness regarding non-invasive treatments. Saudi Arabia and the United Arab Emirates represented 48% of regional HIFU procedure volume because healthcare modernization projects expanded significantly. Prostate disease treatment accounted for 29% of therapeutic ultrasound procedures in the region. Hospitals represented 74% of total HIFU installations because advanced imaging infrastructure remains concentrated in urban medical centers. MRI-guided systems accounted for 33% of regional installations during 2025. South Africa contributed 17% of regional therapeutic ultrasound procedures linked to oncology treatment expansion. Non-invasive uterine fibroid procedures increased by 16% between 2023 and 2025 across women’s health clinics. Portable therapeutic ultrasound systems expanded by 11% in outpatient specialty centers. Limited reimbursement coverage affected 28% of patient treatment accessibility in developing African healthcare systems. AI-assisted imaging integration improved treatment planning accuracy by 14% in regional oncology facilities during 2025.

List of Top High-intensity Focused Ultrasound Therapy Companies

• Insightec
• Chongqing Haifu Medical Technology Co., Ltd.
• Sonablate
• EDAP TMS
• Shanghai A & S Science Technology Development Co.,Ltd
• Profound Medical
• Beijing Yuande Biomedical Engineering Co., Ltd.
• Shanghai A&S Science Technology co.,ltd
• Cardiawave
• Theraclion

List of Top 2 Companies Market Share

• Insightec: accounted for approximately 21% of global high-intensity focused ultrasound therapy installations during 2025 due to strong MRI-guided therapeutic ultrasound portfolios.
• Chongqing Haifu Medical Technology Co., Ltd.: represented nearly 18% of global HIFU therapy system deployment supported by extensive oncology treatment adoption across Asia-Pacific.

Investment Analysis and Opportunities

Investments in the high-intensity focused ultrasound therapy market increased significantly during 2024 and 2025 because healthcare providers prioritized non-invasive oncology treatment technologies. Asia-Pacific accounted for 39% of newly announced HIFU infrastructure projects linked to cancer treatment modernization programs. MRI-guided therapeutic ultrasound systems represented 44% of hospital imaging equipment investments due to higher targeting precision. Oncology-focused HIFU treatment centers increased by 18% globally between 2023 and 2025.

AI-assisted treatment planning software integration improved operational efficiency by 19% in advanced oncology centers. Multi-frequency transducer development projects increased by 16% globally due to demand for higher tissue penetration performance. Emerging economies including India, Thailand, and Indonesia collectively accounted for 22% of newly established therapeutic ultrasound treatment programs during 2025. Public-private healthcare partnerships expanded cancer-focused HIFU infrastructure by 13% across developing healthcare systems.

New Product Development

New product development in the high-intensity focused ultrasound therapy market focused heavily on AI integration, MRI-guided precision, and robotic-assisted therapeutic systems during 2023-2025. MRI-compatible HIFU platforms represented 41% of newly launched therapeutic ultrasound products because imaging precision remains critical in oncology procedures. AI-assisted treatment planning systems improved lesion targeting accuracy by 21% during liver tumor therapy applications. Portable therapeutic ultrasound devices expanded by 18% across outpatient clinics due to increasing demand for same-day procedures.

Robotic-assisted HIFU systems reduced procedural positioning errors by 16% in prostate cancer treatment centers. Multi-frequency transducer technologies improved treatment penetration efficiency by 19% in deep tissue ablation procedures. Real-time thermal monitoring integration increased by 33% among newly developed HIFU therapy systems during 2025. Compact ultrasound-guided systems reduced installation space requirements by 14% in specialty treatment facilities. Non-invasive gynecology-focused HIFU platforms represented 24% of new product launches because uterine fibroid treatment adoption expanded rapidly. Smart imaging software improved treatment workflow efficiency by 17% in oncology clinics. Advanced cooling technologies reduced transducer overheating incidents by 13% during long-duration therapeutic procedures. Wireless monitoring capabilities increased by 15% in newly introduced high-intensity focused ultrasound therapy systems.

Five Recent Developments

• In 2025, Insightec expanded MRI-guided therapeutic ultrasound capabilities with AI-assisted targeting systems improving lesion precision by 19% during neurological treatment procedures.
• In 2024, EDAP TMS upgraded prostate cancer HIFU platforms with robotic positioning technology reducing treatment setup time by 17%.
• In 2025, Profound Medical introduced advanced thermal monitoring integration improving tissue ablation accuracy by 18% in prostate-focused procedures.
• In 2023, Theraclion launched compact outpatient HIFU systems reducing installation space requirements by 14% across specialty clinics.
• In 2024, Chongqing Haifu Medical Technology Co., Ltd. expanded liver tumor therapeutic ultrasound platforms with multi-frequency transducers increasing tissue penetration efficiency by 21%.

Report Coverage of High-intensity Focused Ultrasound Therapy Market

The high-intensity focused ultrasound therapy market report provides comprehensive analysis of treatment technologies, clinical applications, regional demand trends, and competitive developments across global therapeutic ultrasound industries. The report evaluates non-invasive and minimal invasive treatment systems, with non-invasive platforms accounting for 67% of global installations during 2025. Application coverage includes liver tumors, prostate cancer, benign prostate diseases, hysteromyoma, breast cancer, and neurological disorders.

The report analyzes technological trends including AI-assisted treatment planning, robotic-assisted targeting, and real-time thermal monitoring systems. Hospitals represented 71% of therapeutic ultrasound installations globally due to specialized imaging requirements. Prostate cancer applications accounted for 31% of HIFU procedure volume, while gynecological treatment procedures increased by 22% between 2023 and 2025. The report also evaluates regulatory approvals, clinical adoption patterns, infrastructure modernization, and investment trends influencing global therapeutic ultrasound expansion.